1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VEGF inhibition reduces intracranial edema following SRS of brain metastases from renal cell carcinoma
    Meeting Abstract

    Ma, J.; Pike, L. R. G.; Kotecha, R. R.; Carlo, M.; Imber, B. S.; Yamada, Y.; Moss, N.; Beal, K.
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • A proof-of-principle study of split-course bridging radiotherapy prior to commercial CD19 CAR T-cell therapies for patients with relapsed or refractory B-cell lymphomas
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial
    Meeting Abstract

    Musiek, A. C. M.; Whittaker, S.; Horowitz, S. M.; Bagot, M.; Huen, A.; Fisher, D. C.; Haun, P.; Vermeer, M. H.; Ito, T.; Dwyer, K.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Time-to-next-treatment and time-to-next-systemic treatment in patients included in the PROCLIPI registry
    Meeting Abstract

    Quaglino, P.; Ortiz-Romero, P.; Bagot, M.; Cozzio, A.; Evison, F.; Geskin, L.; Guenova, E.; Hodak, E.; Horwitz, S.; Papadavid, E.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol
    Meeting Abstract

    Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Providing nutritional guidance for patients with plasma cell disorders - A missed opportunity for hematologists and oncologists?
    Meeting Abstract

    Sweeney, N.; Malik, M.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P.; Mailankody, S.; Korde, N.; Tan, C.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis
    Meeting Abstract

    Muchtar, E.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelkan, K.; Hegenbart, U.; Dispenzieri, A.; Kumar, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Graded cardiac response criteria for AL amyloidosis: The impact of depth of cardiac response on survival
    Meeting Abstract

    Muchtar, E.; Dispenzieri, A.; Wisniowski, B.; Palladini, G.; Milani, P.; Merlini, G.; Schönland, S.; Veelkan, K.; Hegenbart, U.; Kumar, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Dholaria, B.; Bahlis, N.; Raje, N.; Costello, C.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save